Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysulin is a nutritional supplement formulated to support healthy blood sugar levels and A1c in individuals with Type 2 diabetes, prediabetes, or metabolic syndrome. Developed by Dr. John F. Burd and Lysulin, Inc., the product contains a patented blend of the essential amino acid lysine, elemental zinc, and vitamin C. Its primary mechanism of action involves targeting and reducing protein glycation, a process where excess glucose binds to proteins like hemoglobin, potentially leading to diabetic complications. By inhibiting this process, Lysulin aims to maintain healthy insulin function and overall metabolic health. It is available in various oral forms, including capsules, chewable tablets, and powders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lysulin.